Have the recently completed phase III trials significantly impacted adjuvant treatment choices for stage II breast carcinoma?

E. Middleman*, M. P. Castro, W. Gradishar, M. J. Kane

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Original languageEnglish (US)
JournalSeminars in Oncology
Issue number4
StatePublished - Sep 8 1999

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this